VAL 1000

Drug Profile

VAL 1000

Alternative Names: VAL-1000

Latest Information Update: 27 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Senz Oncology
  • Developer Allyence Research; Senz Oncology
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Cyclin-dependent kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Acute myeloid leukaemia; Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 27 Aug 2015 No recent reports on development identified - Phase-I/II for Acute lymphoblastic leukaemia, Acute myeloid leukaemia and Myelodysplastic syndromes in Australia (PO)
  • 22 Aug 2012 Clinical trials in Leukaemia in Australia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top